European Society of Cardiology (ESC) Congress 2023

Semaglutide scores again, this time for HFpEF in obese

Elvira Manzano, 20231003000000

Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.

OCT- vs angiography-guided PCI for bifurcation lesions: Which is better?

Audrey Abella, 20230922100000

In percutaneous coronary intervention (PCI) for complex bifurcation lesions, optical coherence tomography (OCT) guidance outdid the angiography-guided approach, findings from the OCTOBER* trial have shown.

Acoramidis may be new player in ATTR-CM

Elvira Manzano, 20230921000000

Acoramidis has emerged as an important player in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrating encouraging results in the phase III ATTRibute-CM trial.

Extended anticoagulation benefits cancer patients with distal DVT

Audrey Abella, 20230920100000

In cancer patients with isolated distal deep vein thrombosis (IDDVT), a 12-month anticoagulation regimen with the oral factor Xa inhibitor edoxaban fared better than a 3-month regimen, findings from the ONCO DVT study have shown.

Alirocumab reduces LDL-C in paediatric patients with heterozygous FH

Elaine Soliven, 20230920000000

Alirocumab administered every 2 or 4 weeks (Q2W or Q4W dosing regimen) significantly reduced low-density lipoprotein-cholesterol (LDL-C) levels in paediatric patients with heterozygous familial hypercholesterolaemia (HeFH), according to a study presented at ESC 2023.

Catheter ablation boosts outcomes in patients with advanced HF

Elvira Manzano, 20230919000000

Catheter ablation boosts outcomes in patients with advanced heart failure (HF) who are being considered for heart transplantation or left ventricular assist device (LVAD) implantation in the CASTLE-HTx trial presented at ESC 2023.

Extended clopidogrel monotherapy after DAPT reduces bleeding events in ‘bi-risk’ ACS patients

Elaine Soliven, 20230916000000

Extended clopidogrel monotherapy after a 9- to 12-month course of dual antiplatelet therapy (DAPT) reduces bleeding and ischaemic events in patients with acute coronary syndrome (ACS) who are at high risk for both events, according to the OPT-BIRISK* trial presented at ESC 2023.

Traditional Chinese medicine shows benefit in HFrEF patients

Elaine Soliven, 20230912000000

Treatment with qiliqiangxin (QLQX), a traditional Chinese medicine (TCM), significantly reduces the risk of hospitalization due to heart failure and cardiovascular (CV) death in patients with heart failure and reduced ejection fraction (HFrEF), according to the QUEST* trial presented at ESC 2023

HEART-FID confirms IV iron safety for HF but falls short in efficacy

Audrey Abella, 20230911100000

The HEART-FID trial narrowly missed its primary endpoint, showing modest improvement in all-cause mortality, heart failure hospitalizations (hHF), and exercise function with ferric carboxymaltose (FCM) in HFrEF* patients with iron deficiency (ID).

Pulsed field ablation system as good as standard-of-care ablation for paroxysmal AF

Jairia Dela Cruz, 20230907140000

In the treatment of patients with paroxysmal atrial fibrillation (AF), pulse field ablation (PFA) system appears to yield safety and efficacy outcomes that are noninferior to those of conventional thermal ablation, according to data from the ADVENT trial.